Leucine-485 deletion variant of BRAF may exhibit the severe end of the clinical spectrum of CFC syndrome

J Hum Genet. 2019 May;64(5):499-504. doi: 10.1038/s10038-019-0579-3. Epub 2019 Mar 6.

Abstract

The genotype-phenotype correlation in BRAF variant in cardio-facio-cutaneous (CFC) syndrome is not clearly defined. Here we report a case with a severe clinical phenotype and a novel BRAF variant, p.Leu485del. The present case showed severe intellectual disability, impaired awareness, hyperekplexia, involuntary movements, early onset refractory seizures, and delayed myelination on brain magnetic resonance imaging as well as a polycystic and dysplastic kidney, which are previously unreported anomalies in CFC or RAS/mitogen-activated protein kinase syndromes related to BRAF variant. CFC syndrome, especially caused by BRAF variant, should be included in the differential diagnosis of patients with developmental and epileptic encephalopathies and hyperekplexia. Furthermore, we need to keep in mind that missense variants or the deletion of Leucine-485 may be associated with severe symptoms.

Publication types

  • Case Reports

MeSH terms

  • Amino Acid Sequence*
  • Child, Preschool
  • Ectodermal Dysplasia / genetics*
  • Ectodermal Dysplasia / pathology
  • Facies
  • Failure to Thrive / genetics*
  • Failure to Thrive / pathology
  • Heart Defects, Congenital / genetics*
  • Heart Defects, Congenital / pathology
  • Humans
  • Leucine
  • Male
  • Proto-Oncogene Proteins B-raf / genetics*
  • Sequence Deletion*
  • Severity of Illness Index

Substances

  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf
  • Leucine

Supplementary concepts

  • Cardiofaciocutaneous syndrome